- Home
- ARR vs OGN Comparison
ARR vs OGN Comparison
Compare ARR & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | OGN |
|---|---|---|
| Founded | 2008 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ARR | OGN |
|---|---|---|
| Price | $18.09 | $8.05 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | ★ $17.00 | $14.10 |
| AVG Volume (30 Days) | 3.2M | ★ 5.1M |
| Earning Date | 02-11-2026 | 02-12-2026 |
| Dividend Yield | ★ 15.94% | 0.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.65 | ★ 1.91 |
| Revenue | $116,798,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | $295.68 | N/A |
| Revenue Next Year | $77.90 | N/A |
| P/E Ratio | $27.78 | ★ $4.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.18 | $6.18 |
| 52 Week High | $19.25 | $17.23 |
Technical Indicators
Market Signals| Indicator | ARR | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 66.01 | 66.60 |
| Support Level | $18.02 | $7.08 |
| Resistance Level | $18.33 | $8.49 |
| Average True Range (ATR) | 0.31 | 0.30 |
| MACD | 0.04 | 0.15 |
| Stochastic Oscillator | 66.05 | 76.72 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.